Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0236)
| Name |
Indole-3-pyruvic acid
|
||||
|---|---|---|---|---|---|
| Synonyms |
Indole-3-pyruvic acid; 392-12-1; 3-(1H-Indol-3-yl)-2-oxopropanoic acid; Indole-3-pyruvate; indolepyruvate; 3-Indolylpyruvic acid; Indolepyruvic acid; Indolyl-3-pyruvate; 3-Indolepyruvic acid; 3-(indol-3-yl)pyruvic acid; 3-Indolylpyroracemic acid; 3-(3-Indolyl)-2-oxopropanoic acid; NSC 88874; 1H-Indole-3-propanoic acid, alpha-oxo-; (Indol-3-yl)pyruvate; (indol-3-yl)pyruvic acid; 4QM0LT13A8; 1H-Indole-3-propanoic acid, .alpha.-oxo-; DTXSID3042053; CHEBI:29750; NSC-88874; indol-3-yl pyruvic acid; 3IO; beta-Indolepyruvic acid; beta-Indolylpyruvic acid; Indole-3-pyruvic acid monohydrate; Indole pyruvic acid; EINECS 206-874-1; BRN 0172966; UNII-4QM0LT13A8; 3-indol-3-yl-2-oxopropanoic acid; 3-Indolpyruvic acid; indol-3-pyruvic acid; KETO TRYPTOPHAN; 3-indole-pyruvic acid; .beta.-Indolepyruvic acid; .beta.-Indolylpyruvic acid; bmse000646; bmse000685; 1H-Indole-3-pyruvic acid; Indole-3-Acetylformic Acid; 5-22-06-00324 (Beilstein Handbook Reference); MLS000515792; SCHEMBL125249; CHEMBL485012; DTXCID1022053; HMS2270A21; NSC88874; Tox21_301365; MFCD00005640; STL286879; AKOS005267243; HY-W028393; NCGC00247042-01; NCGC00255790-01; AC-10208; AS-63461; CAS-392-12-1; SMR000112266; 3-(1H-indol-3-yl)-2-keto-propionic acid; Indole-3-pyruvic acid, >=98.0% (TLC); CS-0072417; FT-0627222; C00331; EN300-218335; I-4200; 1H-INDOLE-3-PROPANOIC ACID, .ALPHA.-OXO; A824463; 3-(1H-indol-3-yl)-2-oxidanylidene-propanoic acid; AC17FD8D-94BC-4C87-B5E6-D2B60F03B45D; Q23905803; F9995-2651
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C11H9NO3
|
||||
| IUPAC Name |
3-(1H-indol-3-yl)-2-oxopropanoic acid
|
||||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=CN2)CC(=O)C(=O)O
|
||||
| InChI |
InChI=1S/C11H9NO3/c13-10(11(14)15)5-7-6-12-9-4-2-1-3-8(7)9/h1-4,6,12H,5H2,(H,14,15)
|
||||
| InChIKey |
RSTKLPZEZYGQPY-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Acute myeloid leukaemia | ICD-11: 2A60 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | THP-1 cells | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 |
| MLL/AF4+ RS4 cells | Adult B acute lymphoblastic leukemia | Homo sapiens | CVCL_0093 | |
| HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | |
| HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 | |
| NIH3T3 cells | Normal | Mus musculus | CVCL_0594 | |
| HeLa cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
| Response regulation | Indole-3-pyruvate (I3P) suppresses ferroptosis by direct free radical scavenging and through the activation of an anti-oxidative gene expression program in Childhood acute monocytic leukemia. And I3P elevated the activation of compensatory gene expression as indicated by increased protein amounts of SLC7A11 and HO-1, two important target genes of anti-oxidative stress pathways. | |||